Learn / Clinical Research Management / Data management and trial statistics
Sample size, interim analysis and reporting results
13 minute read · 6-question quiz
What you will learn
Explain the ingredients of a sample size calculation
Calculate a simple sample size for comparing two proportions
Describe interim analyses, multiplicity and the clinical study report
A trial that is too small cannot detect a real effect; one that is too large wastes resources and exposes people unnecessarily. The sample size calculation balances these.
Ingredients
- Primary endpoint and its type (proportion, mean, time to event).
- Expected effect size: the smallest difference worth detecting, and the expected control group rate.
- Significance level (alpha): the chance of a false positive, usually 0.05 (two-sided).
- Power (1 − beta): the chance of detecting a true effect, usually 80% or 90%.
- Variability for continuous outcomes.
- Allowance for dropouts and non-adherence.
Less variability, a larger effect or a lower power requirement all reduce the sample size. A smaller effect, higher power or stricter alpha increase it.
Interim analyses and multiplicity
- Interim analyses look at accumulating data before the end, usually by an independent DSMB, to stop for harm, overwhelming benefit or futility. Each look increases the chance of a false positive, so protocols use stopping boundaries (such as O'Brien-Fleming) that demand stronger evidence early.
- Multiplicity: testing many endpoints, subgroups or time points raises the chance of a false positive. Plans specify a primary endpoint, a hierarchy of secondary endpoints, or adjustments for multiple tests.
The clinical study report
After analysis, the sponsor writes a clinical study report (CSR) following ICH E3: methods, populations, results (efficacy and safety), deviations, and conclusions. Regulators rely on it. Results are also registered and published (covered in the closing chapter).
Summary
Sample size depends on effect size, alpha, power, variability and dropout allowance.
Smaller expected effects need much larger trials.
Interim analyses use stopping boundaries; multiplicity inflates false positives unless controlled.
The CSR (ICH E3) reports methods, results and conclusions.
Check your understanding
Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.